US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer



Assessment Group

$ 8900

In Stock


Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 


Primary research on the oncology prescribing data that you are missing, directly from high-prescribing US oncologists regarding metastatice breast cancer: what they prescribe, when, and why. Case highlights include:


  • Triple negative metastatic breast cancer
  • Triple positive metastatic breast cancer
  • ER/PR positive HER2neu negative metastatic breast cancer
  • Metastatic breast cancer with multiple comorbidities


This report allows you to:


  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing & improving market strategies
  • Pinpoint needs of your target audience
  • Design messages to advance brand performance
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your competitor’s product fits